Oklahoma City, OKNCT06130995Now EnrollingIRB Ready

Androgen Deprivation Therapy Clinical Trial in Oklahoma City, OK

Access cutting-edge androgen deprivation therapy treatment through this clinical trial at a research site in Oklahoma City. Study-provided care at no cost to qualified participants.

Sponsored by University of Oklahoma

Quick Self-Assessment

See if you qualify for this Oklahoma City location

Preparing your pre-screening questions…

Expert Care in Oklahoma City

Access androgen deprivation therapy specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related androgen deprivation therapy treatment provided free

Apply for This Oklahoma City Location

Check if you qualify for this androgen deprivation therapy clinical trial in Oklahoma City, OK

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Oklahoma City

    Convenient for OK residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Oklahoma City site if eligible
  4. 4Begin participation

About This Androgen Deprivation Therapy Study in Oklahoma City

The goal of this clinical trial is to test how effective and safe it is to use a combination of two medications, relugolix and enzalutamide, in patients with advanced prostate cancer. We want to see if this combination can help improve the chances of curing the cancer and make the patients live longer without the cancer getting worse. The main questions we want to answer in this study are: * Can using relugolix and enzalutamide together help increase the chances of curing high-risk advanced prostate cancer? * Does this combination treatment help patients live longer without their cancer getting worse? Participants in this study will be asked to take relugolix and enzalutamide as part of their cancer treatment. They will also undergo Radiation Therapy or prostatectomy, which are standard treatments for this type of cancer.

Sponsor: University of Oklahoma

Who Can Participate

Inclusion Criteria

Capable of giving signed informed consent;
Patients must be ≥18 years of age at the time of signing the informed consent form.
Men with a diagnosis of adenocarcinoma of the prostate pathologically proven diagnosis with the following: • Locally advanced high-risk prostate defined as i. PSA \>20 ng/mL or ISUP grade 4/5 (Gleason score \>7) or cT2c or ii. Any PSA, any ISUP grade, cT3-4 or cN+ (locally advanced)
Have normal organ and bone marrow function measured at the screening visit including
Platelets ≥100 × 103/microliter (μL);
Hemoglobin ≥ 10.0 grams/dL;
Leukocytes (WBC) ≥ 3 × 103/μL;
Absolute neutrophil count ≥1.5 × 103/μL;
Serum AST and ALT ≤2.5 × upper limit of normal (ULN);
Total bilirubin ≤1.5 ×ULN (unless values are consistent with Gilbert's syndrome for which the total bilirubin must be \< 3x ULN);
Serum creatinine ≤ 1.5 × ULN; OR Measured or calculated creatinine clearance ≥30 mL/min for participant with creatinine levels \>1.5 × institutional ULN
Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
The participant has, in the opinion of the investigator, a life expectancy of at least 6 months.
Male patients must be willing to use contraception during treatment and for 3 months after the last dose of study treatment when having sexual intercourse with a pregnant woman or with a woman of childbearing potential. Female partners of male patients should also use a highly effective form of contraception if they are of childbearing potential.

Exclusion Criteria

History of major adverse cardiac event, including myocardial infarction, new congestive heart failure (CHF) or CHF exacerbation, or stroke, within the past 6 months.
Patients who are receiving any other investigational agents.
Patients with distant metastatic cancer will be excluded from the study as intermittent hormonal therapy is not standard of care treatment for this population.
Active secondary malignancies requiring treatment
History of allergic reactions attributed to compounds of similar chemical or biologic composition to any of study drugs
Participants with uncontrolled intercurrent illness.
Participant is unable to swallow pills.
Not a candidate for surgical or radiation therapy

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Oklahoma City?

Yes, this clinical trial (NCT06130995) has an active research site in Oklahoma City, OK that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Androgen Deprivation Therapy Treatment Options in Oklahoma City, OK

If you're searching for androgen deprivation therapy treatment options in Oklahoma City, OK, this clinical trial (NCT06130995) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Oklahoma City research site is actively enrolling participants for this clinical trial. You'll receive care from experienced androgen deprivation therapy specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all androgen deprivation therapy clinical trials near you to find additional studies recruiting in your area.

More Rheumatoid Arthritis Trials in Oklahoma City, OK

See all rheumatoid arthritis clinical trials recruiting in Oklahoma City — not just this study.

Browse Rheumatoid Arthritis Trials in Oklahoma City →

Browse More Trials by Condition

Rheumatoid Arthritis TrialsAll Conditions →

Ready to Join in Oklahoma City?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Oklahoma City, OK